PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to estimate the efficacy and safety of PEG-rhG-CSF in patients with breast cancer receiving chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Patients with age between 18 and 70 years

• diagnosis of breast cancer patients who need to receive multi-cycle chemotherapy

• grade III/IV neutropenia after chemotherapy

• KPS score≥70

• life expectancy of at least 3 months

• Written informed consent are acquired

Exclusion Criteria:

• Have accepted any other drug related clinical trial within 4 weeks before anticipated

• uncontrolled infection

• pregnancy

• Other situations that investigators consider as contra-indication for this study